Liver protein and metabolite biolabels reveal hepatoprotective effects and active compounds of Eucommiae folium: Exploration of new application of herb based on multi-omics and bioinformatics

• Published in: Journal of pharmaceutical and biomedical analysis Vol. 239; p. 115870
• Main Authors: Zhang, Shuai-Nan, Liu, Qi, Li, Xu-Zhao, Yang, Wu-De, Zhou, Ying
• Format: Journal Article
• Language: English
• Published: England 15.02.2024
• Subjects: Animals; Computational Biology; Liver Cirrhosis - chemically induced; Liver Diseases; Mice; Multiomics; Biolabel; Eucommiae folium; Oxidative phosphorylation; Bioinformatics; Liver cirrhosis; Multi-omics
• ISSN: 0731-7085; 1873-264X
• DOI: 10.1016/j.jpba.2023.115870

A biolabel-led research based on multi-omics and bioinformatics was applied to analyze the application value of Eucommiae folium (EF) in liver cirrhosis, as well as the mechanism of action and material basis. Multi-omics were used to analyze the biolabels and key pathways of EF intervention in liver tissue. Subsequently, based on the information, bioinformatics was used to analyze the application value of EF in liver disease, as well the mechanism of action and material basis. Finally, histopathological and target expression analyses in an animal model were used to verify biolabels analysis results. Multi-omics showed that 18 proteins and 10 metabolites involved in five key pathways were screened as biolabels. Bioinformatics suggested that the application value of EF for liver cirrhosis may be the highest among the liver diseases that it may treat. Additionally, EF and five active compounds (curcumol, eucalyptol, (+)-catechin, naringenin, and quercetin) may protect the cirrhotic liver against the excessive energy expenditure and hepatic stellate cells activation through suppressing the oxidative phosphorylation pathway in a CCl -induced mouse model. This study provides reference and evidence for the application value of EF in liver diseases, especially liver cirrhosis.